Atezolizumab

Active substance Atezolizumab
Domain Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen Indication extension
Main indication Breast cancer
Extended indication treatment of patients with previously untreated metastatic TNBC in combination with paclitaxel

Product

Proprietary name Tecentriq
Manufacturer Roche
Mechanism of action PD-1 / PD-L1 inhibitor
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional comments IMpassion131

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date October 2020
Expected Registration September 2021
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Current treatment options Chemotherapie - trastuzumab - pertuzumab
Therapeutic value No judgement
Duration of treatment Not found
Frequency of administration 1 times every 2 weeks
Dosage per administration 840 mg
References NCT03125902

Expected patient volume per year

References NKR 2016
Additional comments 1.687 diagnoses mammacarcinoom HR-, HER-. Hiervan betreft het 563 patiënten in stadium 1, 747 patiënten in stadium 2, 239 patiënten in stadium 3 en 134 patiënten in stadium 4. Echter de inschatting is dat de combinatie met paclitaxel nauwelijks zal worden toegepast in Nederland.

Expected cost per patient per year

Cost 30,000.00 - 50,000.00
Additional comments Afhankelijk van behandelduur. Deze is op dit moment onbekend. Om die reden op basis van andere indicaties van atezolizumab de inschatting gemaakt dat deze mogelijk €30.000 -€50.000 per patiënt per jaar kan gaan kosten. Voor alle indicaties van atezolizumab geldt een financieel arrangement die is voortgekomen uit de onderhandelingen in de sluis (lopend tot en met 31 december 2020).

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions zie indicatie-uitbreidingen in de Horizonscan op het gebied van: huidkanker, longkanker, leverkanker, blaaskanker, nierkanker en borstkanker
References Horizonscan

Other information

There is currently no futher information available.